David Dally

BlueCrest Capital Management (UK) LLP (BCM-UK) is an independent, Great Britain-based alternative asset management firm headquartered in London. The firm was founded in 2009 by Michael Platt and Bill Reeves to manage their flagship fund, BlueCrest Capital International. In 2015, they transitioned to a Private Investment Partnership and returned client capital. BCM-UK currently manages assets solely on behalf of their partners and employees.

First Light Fusion Ltd. manages a research intensive company in energy and process engineering. It engages in developing technology for inertial confinement fusion, using a radically different approach. The firm discovers implosion processes for electricity generation. The company was founded by Yiannis Ventikos and Nicholas Hawker in 2011 and is headquartered in Begbroke, the United Kingdom.

Intelligent Ultrasound Ltd. provides ultrasound software solution. Its IQA Audit offers users a comprehensive, independently conducted audit of ultrasound images stored as part of the patient record. The firm's IQA Metrics provides managers and users with metrics, derived from data recorded from the ultrasound equipment during use, to support decision-making. The company was founded by Aris Papageorghiou, Alison Noble and Andrew Hill and is headquartered in Abingdon, the United Kingdom.

Deontics Ltd. provides clinical software to process scientific information. It commercializes clinical pathways and clinical decision support systems developed at cancer research UK, oxford university and university college london. The company was founded by John Fox, Guy Wood-Gush and Ioannis Chronakis and is headquartered in London, the United Kingdom.

Oxsight Ltd. provides research and experimental development on natural sciences and engineering services. The firm specializes in augmented reality, image interpretation, smart glasses, customer care, agile development and wearable technology. The company was founded by Stephen Lloyd Frederick hicks and Philip Torr and is headquartered in Oxford, the United Kingdom.

Mazza Innovation Ltd. provides plant extraction technology. Its products include PhytoClean which yields clean ingredients in an earth-friendly manner from plants. The company was founded by Giuseppe Mazza, Carl Pronyk, and Eduardo Cacace in August 2011 and is headquartered Delta, Canada.

Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom.

Ichnos Sciences, Inc. operates as a biotechnology company. It provides curative therapies that extend human life. The company was founded in 2019 and is headquartered in Paramus, NJ.

The General Medical Council provides business support services. The non-profit company is based in London, UK. The CEO of the British company is Charlie Massey.

American Association for Cancer Research prints and publishes scientific journals including clinical cancer research, molecular cancer therapeutics, molecular cancer research, cancer epidemiology, and biomarkers and prevention. The company was founded on May 7, 1907 and is headquartered in Philadelphia, PA.

The American Society of Clinical Oncology is a non-profit organization founded in 1964 with the overarching goals of improving cancer care and prevention. More than 27,000 oncology practitioners belong to ASCO, representing all oncology disciplines and subspecialties. Members include physicians and health-care professionals in all levels of the practice of oncology. American Society of Clinical Oncology is the world’s leading professional organization representing physicians who treat people with cancer. ASCO’s members set the standard for patient care worldwide and lead the way in carrying out clinical research aimed at improving the prevention, diagnosis, and treatment of cancer. ASCO's efforts are also directed toward advocating for policies that provide access to high-quality care for all patients with cancer and at supporting the increased funding for clinical and translational research.

Georgiamune, Inc. is a clinical stage biotechnology company that focuses on reprogramming immune signaling pathways to redirect the immune system to fight diseases. The company is based in Silver Spring, MD. The company has designed unique approaches to re-establish immune balance, and its scientific discoveries have led to pioneering immunotherapies targeting high unmet needs. Georgiamune's lead program, Gim-122, is a first-in-class, dual-functioning monoclonal antibody designed to overcome immune therapy resistance in cancer patients. In addition to its lead program, the company is advancing a pipeline of first-in-class therapies for cancer and autoimmune diseases. The company was founded by Samir N. Khleif, a world-renowned medical oncologist and researcher in the field of immunology and cancer, based on discoveries in his lab on novel mechanisms to modulate immune response. Samir N. Khleif has been the CEO since incorporation.

Technikos LLP (Technikos) is a venture capital firm founded in 2006. The firm is headquartered in London.

Accovion GmbH operates as a contract research organization, which offers planning and conducting of clinical drug tests, data collection, and processing. It also provides services in the areas of design, analysis, and creation of statistical and clinical reports. The firm also specializes in biometrical planning and evaluation, pharmaco-economic studies, as well as quality control and assurance. The company was founded on May 22, 2001 and is headquartered in Eschborn, Germany.

BC Capital Management Services Ltd. operates as an alternative investment manager. The company was founded in 2000 and is headquartered in London, the United Kingdom.

BlueCrest Capital Management Ltd. (BlueCrest) is a single-family office headquartered in St. Helier, UK. They are a subsidiary of WHR Investments Ltd., ultimately owned by BC Cayman Charitable Trust in Cayman Islands. The firm was previously a hedge fund management firm and in 2015, Michael Platt decided to turn BlueCrest into a firm that only managed his own money and money that belongs to BlueCrest partners and employees.

Sensovation AG manufactures and supplies scientific imaging instrumentation products. The firm specializes in the development and production of scientific imaging and low light detection solutions, based on charge coupled device and complementary metal oxide semiconductor technologies. It offers automated digital microscopes, microarray analyzers, and scientific cameras for bioimaging, diagnostics, and quality control in clean technology applications. It also engages in partnerships focused on building and supplying commercial production systems and platforms. The company was founded by Stefan Bickert and Paul Hing in 2000 and is headquartered in Radolfzell, Germany.

HeidelbergCapital Asset Management GmbH (HCAM) is an independent private equity firm established in 2007 with backing from New York-based private equity investor Auda International, controlled by the Harald Quandt family. HCAM is located in Heidelberg in southwestern Germany. The firm specializes in private equity secondaries.

Part of Sotera Health Co., Phoenix International Life Sciences, Inc. is a Canadian company that provides bioanalytical research and clinical testing services. The company is based in Saint-Laurent, Canada. Phoenix International Life Sciences was acquired by Nordion (Canada), Inc., part of Sotera Health Co. from July 30, 2018 on May 22, 2000 for $236.74 million.

vasopharm GmbH operates as a pharmaceutical company. It discovers and develops novel therapeutics for the treatment of cerebro and cardiovascular diseases and their consequences. The firm focuses on therapeutics influencing the bioavailability of nitric oxide. The company was founded by Harald Schmidt and Ulrich Walter in July 1998 and is headquartered in Wuerzburg, Germany.

Ariceum Therapeutics GmbH is a German clinical stage radiopharmaceutical company that focuses on the diagnosis and precision treatment of certain neuroendocrine and other aggressive, hard-to-treat cancers. Ariceum Therapeutics is based in Berlin, DE, and has subsidiaries in various locations worldwide. The company's lead targeted systemic radiopharmaceutical product, -satoreotide tetraxetan ("satoreotide"), is an antagonist of the somatostatin type 2 (sstr2) receptor, which is overexpressed in neuroendocrine tumors (NETs) and some aggressive cancers such as small cell lung cancer (SCLC) and Merkel cell carcinoma. Ariceum is also developing a radiolabeled PARP-inhibitor (ATT-001), which is slated to enter the clinic in early 2024. The company was founded in 2021, and Manfred Rüdiger has been the CEO of the company since 2021.